BioVex Report issue

Contributed to NME For profit Phase 3
Founded: Oxton United Kingdom (2006)
Status: Acquired by Amgen (2011)

Organization Overview

First Clinical Trial
2006
NCT00289016
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BioVex Limited

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Squamous Cell (Phase 3)

Head and Neck Neoplasms (Phase 3)

Melanoma (Phase 3)

Pancreatic Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 3